Safety Observation of the Vero Cell-derived Inactivated Japanese Encephalitis Vaccine (JEV-I) Given With Primary Immunization in a Large Amount of Healthy Children Aged 8 Months and Older
Status: Completed
Location: See location...
Study Type: Observational
SUMMARY
This is a single-arm, non-randomized, open-label post-marketing safety observation study. The purpose of this study is to investigate the safety of JEV-I given with primary immunization in a large amount of healthy children aged 8 months and older.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 8 months
Healthy Volunteers: t
View:
• Healthy children who have received the inactivated Japanese encephalitis vaccine.
• Legal guardian of the participants voluntarily participates in the clinical trial and signs an informed consent form.
• Legal guardian of the subject has the ability to understand the procedures of the study and accept all scheduled visits.
Locations
Other Locations
China
Jiangsu Provincial Center for Disease Control and Prevention
Nanjing
Time Frame
Start Date: 2024-01-01
Completion Date: 2025-04-30
Participants
Target number of participants: 15357
Treatments
Vero Cell-derived Inactivated Japanese Encephalitis Vaccine Group
Healthy children aged 8 months and above who choose to receive the study vaccine for primary immunization at their own expense in Jiangsu Province
Related Therapeutic Areas
Sponsors
Leads: Liaoning Chengda Biotechnology CO., LTD